Mikunis R I, Monastyrskiĭ Iu I, Pshelutskiĭ F F, Serkova V K, Demidiuk V T
Kardiologiia. 1988 Dec;28(12):51-3.
Hypotensive effect of foridon was evaluated in 68 patients with first- and second-stage essential hypertension, 17 patients with renal hypertension and 18 patients with pulmonary hypertension. Changes in clinical condition, central hemodynamics, pulmonary arterial systolic pressure, inhalation and exhalation intensity were assessed. Foridon effect was shown to be largely due to reduced peripheral resistance. Foridon (30-60 mg) was effective in first-stage essential hypertension. In second-stage hypertension, foridon alone did not always produce an effect. In such cases, foridon-clofelin combination where clofelin hypotensive effect is enhanced can produce a marked hypotensive effect. Foridon is not indicated for the treatment of renal hypertension. Its use as part of combined treatment for chronic nonspecific pulmonary diseases where it is to reduce pulmonary hypertension, is justified.
对68例一期和二期原发性高血压患者、17例肾性高血压患者及18例肺动脉高压患者评估了福立顿的降压效果。评估了临床状况、中心血流动力学、肺动脉收缩压、吸入和呼气强度的变化。结果显示，福立顿的作用主要是由于外周阻力降低。福立顿（30 - 60毫克）对一期原发性高血压有效。在二期高血压中，单独使用福立顿并不总能产生效果。在这种情况下，福立顿与可乐定联合使用（可乐定的降压作用会增强）可产生显著的降压效果。福立顿不适用于肾性高血压的治疗。在慢性非特异性肺部疾病的联合治疗中使用福立顿以降低肺动脉高压是合理的。
